본문으로 건너뛰기
← 뒤로

Adequacy of clinical guideline recommendations for patients with low-risk cancer managed with monitoring: systematic review.

메타분석 1/5 보강
Journal of clinical epidemiology 2024 Vol.169() p. 111280
Retraction 확인
출처

Collins KK, Smith CF, Ford T, Roberts N, Nicholson BD, Oke JL

📝 환자 설명용 한 줄

[OBJECTIVES] The aim of this systematic review was to summarize national and international guidelines that made recommendations for monitoring patients diagnosed with low-risk cancer.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P = 0.001
  • 연구 설계 systematic review

이 논문을 인용하기

↓ .bib ↓ .ris
APA Collins KK, Smith CF, et al. (2024). Adequacy of clinical guideline recommendations for patients with low-risk cancer managed with monitoring: systematic review.. Journal of clinical epidemiology, 169, 111280. https://doi.org/10.1016/j.jclinepi.2024.111280
MLA Collins KK, et al.. "Adequacy of clinical guideline recommendations for patients with low-risk cancer managed with monitoring: systematic review.." Journal of clinical epidemiology, vol. 169, 2024, pp. 111280.
PMID 38360377 ↗

Abstract

[OBJECTIVES] The aim of this systematic review was to summarize national and international guidelines that made recommendations for monitoring patients diagnosed with low-risk cancer. It appraised the quality of guidelines and determined whether the guidelines adequately identified patients for monitoring, specified which tests to use, defined monitoring intervals, and stated triggers for further intervention. It then assessed the evidence to support each recommendation.

[STUDY DESIGN AND SETTING] Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses, we searched PubMed and Turning Research into Practice databases for national and international guidelines' that were written in English and developed or updated between 2012 and 2023. Quality of individual guidelines was assessed using the AGREE II tool.

[RESULTS] Across the 41 published guidelines, 48 different recommendations were identified: 15 (31%) for prostate cancer, 11 (23%) for renal cancer, 6 (12.5%) for thyroid cancer, and 10 (21%) for blood cancer. The remaining 6 (12.5%) were for brain, gastrointestinal, oral cavity, bone and pheochromocytoma and paraganglioma cancer. When combining all guidelines, 48 (100%) stated which patients qualify for monitoring, 31 (65%) specified which tests to use, 25 (52%) provided recommendations for surveillance intervals, and 23 (48%) outlined triggers to initiate intervention. Across all cancer sites, there was a strong positive trend with higher levels of evidence being associated with an increased likelihood of a recommendation being specific (P = 0.001) and the evidence for intervals was based on expert opinion or other guidance.

[CONCLUSION] With the exception of prostate cancer, the evidence base for monitoring low-risk cancer is weak and consequently recommendations in clinical guidelines are inconsistent. There is a lack of direct evidence to support monitoring recommendations in the literature making guideline developers reliant on expert opinion, alternative guidelines, or indirect or nonspecific evidence.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (2)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반